Phaseline

Companies › Healthgen Biotechnology

Healthgen Biotechnology: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 2; Gastroenterology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dimethicone emulsion
Antifoaming agent; reduces gastric foam to improve mucosal visibility
–Phase 2Gastric Mucosal Lesion–
OsrHSA
Recombinant human serum albumin expressed in rice plants (Oryza sativa)
–Phase 2Cirrhotic Ascites–
Recombinant Human Chymotrypsin (OsrhCT)
Serine protease; mucolytic enzyme to improve gastric mucosa visualization
CTRLPhase 2Gastric Mucosal Lesion–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04835480OsrHSAPhase 2Cirrhotic AscitesGastroenterologyJun 2022
NCT06722664Recombinant Human Chymotrypsin (OsrhCT)Phase 2Gastric Mucosal LesionGastroenterologyMay 2025
NCT06722664Dimethicone emulsionPhase 2Gastric Mucosal LesionGastroenterologyMay 2025

Targets

CTRL (1)

Companies with the same targets

–

Companies built like this

NorthSea Therapeutics TRYP Therapeutics Dr. Falk Pharma Napo Therapeutics Panafina

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.